Introduction {#S1}
============

Diabetes, one of the most prevalent metabolic disorders, is estimated to affect 400 million or 4.4% of population worldwide in the next 20 years \[[@R1],[@R2]\]. Vascular abnormalities are the major contributor to the progression of diabetes which is associated with complications often linked to the increased morbidity and mortality. In diabetic patients, coronary artery disease and peripheral vascular diseases are increased to 2- to 4-fold and 10-fold, respectively, compared to non-diabetic individuals.

The endothelium is a monolayer of endothelial cells (ECs) lining the lumen of all blood vessels and functions as a protective biocompatible barrier between tissues and circulating blood. In human, there is a range of 1--6×10^13^ ECs covering the surface area of more than 1,000 square meters of endothelium \[[@R3],[@R4]\]. The endothelium plays a key role in the control of vasomotor tone and organ perfusion, and contributes to regulation of arterial blood pressure, by releasing vasodilator substances and vasoconstrictor substances \[[@R5],[@R6]\]. Endothelial dysfunction (ED) is a systemic pathological condition, which can be characterized by an impairment of endothelium-dependent vasodilatation. ED is an early event in the development of cardiovascular disease prior to any visible morphological changes in endothelium. Recently, ED has been linked to endothelial activation \[[@R7]\] including increased interaction between inflammatory cells/factors (leukocytes, intercellular adhesion molecule, vascular cell adhesion molecule 1 and selectins) and endothelial cells, and albumin leakage. Numerous studies have showed that the endothelial function is impaired in both diabetic patients and animals. Therefore, understanding the underlying mechanisms of ED may provide novel promising therapeutic strategies for the treatment of cardiovascular diseases in diabetes.

Calpains are a family of cytosolic calcium-dependent cysteine-proteases which tightly regulate their respective substrates through limited proteolytic cleavage. Elevated calpains expression or activity has been found in patients \[[@R8]\] and experimental animals \[[@R9],[@R10]\] with diabetes. Inhibition of calpains activity rescues hyperglycemia-mediated vascular injury, inflammation and ED \[[@R9],[@R10]\].

Endothelial nitric oxide (NO) was first recognized as a major vasodilator involved in control of vasomotor function and local blood flow. Endothelial NO is mainly generated by constitutively active endothelial NO synthase (eNOS), an essential enzyme responsible for vascular homeostasis. Loss of NO bioavailability as a result of decrease of eNOS activity has been speculated to play an essential role in the pathogenesis of ED. In this review, we summarize the current understanding of the role of calpains activation and signaling pathways in NO-mediated ED in diabetes.

Calpain Family {#S2}
==============

There are currently 15 known human calpain isoform genes. Members of the calpain family are believed to function in various biological processes, including integrin-mediated cell migration, cytoskeletal remodeling, cell differentiation and apoptosis \[[@R11]\]. Activation of calpain has been implicated in the acute and chronic hyperglycemia (HG)-induced ED \[[@R9],[@R10]\], platelet hyperaggregability \[[@R12]\], neurovascular dysfunction \[[@R13]\] and cardiomyocyte apoptosis \[[@R12]\] in diabetes. Within the calpain family, micro (μ)- and milli (m)-calpain are the two most well characterized isoforms. μ- and m-calpain are ubiquitously expressed in mammals, and are activated by micro-and millimolar calcium concentrations in vitro, respectively \[[@R11]\]. Both proteins are heterodimers composed of a large 78--80 kDa catalytic subunit and a common small 29 kDa regulatory subunit \[[@R14]\]. The large subunit comprises four domains (dI-dIV), whereas the small subunit has two domains (dV-dVI). When calpains are activated, they undergo autoproteolysis which removes N-terminal in dI (NT, 27 and 19 amino acids from large subunit (catalytic subunit) of μ- and m-calpain, respectively) \[[@R14]\]. Thus lowers levels of calpain large subunit NT indicates higher degrees of proteolytic activity of calpain \[[@R1],[@R15]\]. Total μ- and m-calpain content was quantified using a primary antibody against the stable domain IV of the large subunit, which recognizes both unautolyzed and autolyzed μ- and m-calpain \[[@R1],[@R15]\]. Previously, it was considered that the calcium influxes are mainly responsible for the activation of calpains. However, the calcium concentrations required for its activation in vitro are much higher compare to that in the physiological condition (100 nM to 10 μM) and not consistent with cell survival. Several mechanisms have been suggested for calpains activation in the presence of lower calcium concentration, such as mitochondrial translocation of calpains via increasing mitochondrial oxidative stress \[[@R16]\] and posttranslational modifications of calpains by kinases thus indirectly activate calpains by increasing its sensitivity to calcium \[[@R17]\]. Activation of μ-calpain is also regulated by its membrane localization and by its binding to phosphatidylinositol \[[@R18]\]. Moreover, Na^+^/H^+^ exchanger is required in hyperglycemia-induced calpains activation \[[@R19]\].

Both μ- and m-calpain are specifically countered by the endogenous calpain inhibitor, calpastatin \[[@R11]\]. Several substrates for calpains have been identified, including cytoskeletal proteins, membrane receptors, protein kinases, and transcription factors \[[@R11]\].

Calpains in Diabetes {#S3}
====================

Calpain-10 is the first calpain gene identified in diabetes. The polymorphism of calpain-10 has been linked and associated with diabetes susceptibility, glucose homeostasis, insulin secretion and insulin activation \[[@R20],[@R21]\]. Decreased calpain-3 expression in skeletal muscle is associated with obesity and insulin resistance and linked to diabetes mellitus \[[@R22]\].

The μ-calpain (calpain-1) is activated in diabetes. Activation of μ-calpain has been suggested to be linked to impairment of glucose transporter turnover \[[@R23]\] and ED \[[@R9],[@R10],[@R1],[@R24]\]. Acute exposure of mouse pancreatic islets to μ-calpain decreased insulin-stimulated glucose uptake into adipocytes, skeletal muscle, and glycogen synthesis in muscle. Inhibition of μ-calpain by μ-calpain antisense oligonucleotides or siRNA rescued high glucose-induced ED and vascular inflammation in the micro- and macro-vasculature \[[@R9],[@R10],[@R1],[@R24]\].

Taken together, calpains, especially calpain-10 and −3, and μ-calpain play an important role in the pathogenesis of diabetes, such as insulin resistance, insulin secretion, glycogen synthesis, glucose transporter turnover and ED. Different calpain seem to serve unique roles in the pathogenesis of diabetes, thus discovery of selective calpain inhibitors are critically for the treatment of cardiovascular complications in diabetes.

Calpain Activation in ECs {#S4}
=========================

Both μ- and m-calpain are expressed in vascular cells, including ECs and vascular smooth muscle cells (VSMCs). The role of calpains in regulation of EC functional properties has been extensively examined. Calpains act on ECs, thus maintaining vascular physiological integrity \[[@R25]--[@R27]\]. Whereas, over activation of calpains appears to play an important role in pathogenesis of angiogenesis \[[@R11],[@R28]\], ED \[[@R9],[@R10],[@R24],[@R29]\] and wound healing \[[@R30]\]. Many factors have been suggested to induce calpains activation in ECs ([Figure 1](#F1){ref-type="fig"}). Vascular endothelial growth factor increased μ-calpain activity in both human microvascular and bovine aortic endothelial cells \[[@R11],[@R31]\]. Shear stress increased μ-calpain activity in mouse aortic and human umbilical vein endothelial cells (HUVECs) \[[@R11],[@R26],[@R32]\]. Angiotensin II induces μ-calpain activation in the endothelia cells of mouse postcapillary venules \[[@R29]\]. Hypoxia induces calpains activation in porcine pulmonary artery ECs \[[@R33]\]. Moreover, oxidized LDL enhanced μ-calpain activity in HUVECs \[[@R34]\]. Antioxidants reduced μ-calpain but not m-calpain activity in mouse pulmonary microvascular endothelial cells. High glucose increases μ-calpain activity in HVECs \[[@R35]\] and mouse micro- and macro-vascular ECs \[[@R9],[@R10],[@R15],[@R24]\].

Hyperhomocysteinemia (HHcy) - elevated plasma homocysteine (Hcy) concentration has been considered as an independent risk factor for the development of ED \[[@R6],[@R15],[@R36]\]. Recent studies shown a high prevalence of HHcy in patients with diabetes and that plasma concentration of Hcy is positively correlated with cardiovascular mortality and morbidity in diabetes \[[@R37]\]. However the interaction between HHcy and diabetes and the role of HHcy/diabetes on the pathogenesis of cardiovascular diseases remains incompletely understood. We and other groups have shown that HHcy increased μ-calpain activity in micro- and macro-vascular ECs \[[@R15],[@R16]\]. Calpain activity is increased in mice with HHcy and cultured rat heart microvascular ECs \[[@R16],[@R38]\]. Moreover, HHcy induces the translocation of active μ-calpain from cytosol to mitochondria, leading to increased intramitochondrial oxidative stress in cultured rat heart microvascular endothelial cells \[[@R16]\]. We recently studied the effect of HHcy on hyperglycemia-induced calpains activation \[[@R15]\]. We found that D-Hcy (500 μM) for 48 hours potentiated D-glucose (25 mM)-induced calpains activation in both human and mouse aortic endothelial cells \[[@R15]\]. Moreover, μ-calpain siRNA significantly inhibited HHcy/hyperglycemia-induced calpains activity. By our knowledge, we are the first to report that HHcy potentiates hyperglycemia-induced μ-calpain activation in macro-vascular ECs \[[@R15]\]. We believe that our findings will provide fundamental insights for the prevention and treatment of cardiovascular diseases in patients with diabetes and HHcy.

Calpains-induced ED in Diabetes {#S5}
===============================

In response to pathophysiological stimulation, the endothelium maintains vascular hemostasis by releasing vasodilator substances, such as nitric oxide (NO), prostacyclin (PGI~2~) and endothelium-derived hyperpolarizing factor (EDHF), and vasoconstrictor substances, such as angiotension II, endothelin-1, thromboxane A~2~, and prostaglandin H~2~ \[[@R5],[@R6]\]. ED is characterized by and often defined as a reduced response to an endothelium-dependent vasodilator substances, such as acetylcholine or bradykinin, or to flow-mediated vasodilatation \[[@R39]\].

Therefore, understanding the effect of calpains on the vasodilator substances and underlying mechanisms could provide therapeutic insight in the prevention and treatment of ED in diabetes. In fact, accumulative evidence showed that inhibition of calpains rescued ED and prevented interaction between inflammatory cells (leukocytes)/factors (intercellular adhesion molecule-1 and vascular cell adhesion molecule-1) with ECs in diabetes ([Table 1](#T1){ref-type="table"}) \[[@R9],[@R10],[@R13],[@R15],[@R24],[@R40],[@R41]\]. However the underlying mechanisms remain unclear.

Effects of calpains activation on eNOS expression/activity and eNOS signaling pathways have been extensively studied. NO production in ECs is modulated through calpains-induced proteolysis of eNOS-associated proteins, such as heat shock proteins 90 (hsp90) \[[@R42]\], caveolin \[[@R42]\], eNOS itself \[[@R31],[@R34]\], Akt \[[@R43]\] or interruption of Akt, hsp90 and eNOS binding \[[@R9],[@R10],[@R43]\] or regulation of PI~3~K/AMPK signaling \[[@R31]\]. Activation of calpains also leads to disruption of eNOS localization by caveolin-3 breakdown in caveolae structures thus induces aberrant eNOS uncoupling \[[@R44]\].

Protein kinase C (PKC) is an important signaling molecule associated with ED in diabetes. Activation of endothelial PKC induces ED in diabetes via regulation of vasodilators and vasoconstrictors \[[@R45],[@R46]\]. Within the PKC family, PKCβ~2~ has received much attention since it was first shown to be preferentially in diabetic vascular tissue \[[@R47]\]. PKCβ~2~ activation mediates HG-induced microvascular inflammation \[[@R48]\] and cardiomyocyte apoptosis \[[@R12]\]. Originally, PKC was found as a substrate of the calpains family which can be cleaved and activated by calpains activation \[[@R49],[@R50]\].

Recent studies suggested that calpains can also serve as a downstream target of PKC signaling \[[@R51]\]. PKC inhibitor BIM-1 decreases calpains activity in mouse microvascular endothelial cells under hyperglycemia condition \[[@R48]\]. Nevertheless, we recently showed that both μ-calpain and PKCβ~2~ inhibition by pharmacological inhibitors or gene silencing approaches rescued HHcy/hyperglycemia-induced eNOS-pThr495 \[[@R15]\]. We demonstrated that HHcy potentiated hyperglycemia-induced ED via μ-calpain/PKCβ~2~ activation-mediated eNOS-pThr49, eNOS inactivation and NO reduction \[[@R15]\].

PGI~2~ is generated from arachidonic acid by cyclooxygenase (COX) including COX-1 and COX-2. PGI~2~ mediates endothelium-dependent vascular relaxation via PGI~2~ receptors (IP) and protects vessels from the development of diseases \[[@R52]\]. Decreased production of PGI~2~ has been suggested to cause an increased incidence of cardiovascular events \[[@R53]\].

In diabetes, PGI~2~ may also act on thromboxane prostanoid receptor (TP) on smooth muscle to mediate vasoconstriction and it functions as an endothelium-dependent contracting factor \[[@R54]\]. COX-2 has been commonly considered a major source of endothelial PGI~2~ synthesis \[[@R53]\]. The role of calpain on the regulation of COX-2 in diabetes remains unclear. Calpain/cathepsin protease inhibitors suppressed cleavage of COX-2 in human synovial fibroblasts \[[@R55]\]. Calpain inhibitor PD150606 dose-dependently increased lipopolysaccharide-induced COX-2 in murine aortic endothelial cells (MAEC), which was dose-dependently degraded by porcine μ-calpain \[[@R56]\].

Moreover, titanium particles stimulate COX-2 expression in fibroblasts via calpain-induced degradation of IκB and activation of NF-κB \[[@R57]\]. Thus, studies on the role of calpain activation on the impairment of PGI~2~-mediated endothelium-dependent vascular relaxation in diabetes are needed.

Cumulative evidence is mounting that EDHF is a major determinant of vascular tone in small resistance vessels. In spite of numerous studies, the nature of EDHF is still not entirely elucidated. The endothelium-mediated relaxation, which is resistant to eNOS and COX inhibition, is thought to be mediated by EDHF. Current evidence suggests that EDHF-mediated responses are initiated by activation of endothelial K^+^ channels (Kca), thus posttranscriptional modification of KCa is suggested to be involved in EDHF-mediated ED under certain disease conditions \[[@R6],[@R36],[@R58]\]. We have found that EDHF-mediated endothelium-dependent vascular relaxation was impaired in the mesenteric artery of diabetic Goto-Kakizaki rats and this relaxation was aggravated by high-salt diet \[[@R59]\]. Moreover, we reported that HHcy impaired EDHF-mediated ED in mouse small mesenteric artery by oxidation and tyrosine-nitration of small and intermediate conductance Kca \[[@R36]\]. Role of calpain on the regulation of Kca in ECs has not been studied under diabetic condition yet. A recent study showed that over expression of endogenous calpain inhibitor calpastatin improved EDHF-mediated ED in the aorta of streptozotocin (STZ)-treated mice, suggesting that activation of calpains may also trigger ED in diabetes via regulation of EDHF. Further studies on the effects of calpain activation on the regulation of EDHF-mediated endothelial dysfunction in diabetes are warranted.

Conclusions {#S6}
===========

Our study and data from other laboratories support the concept that activation of calpains, especially activation of μ-calpain, is causally linked to NO-mediated ED in diabetes. Activation of μ-calpain decreases NO bioavailability by decreasing the interaction between hsp90 and eNOS, increasing eNOS degradation and eNOS-pThr495 ([Figure 2](#F2){ref-type="fig"}). Inhibition of calpains rescued hyperglycemia-induced NO-mediated ED and inflammatory responses in micro- and macro-vasculature. We demonstrate that HHcy potentiates μ-calpain activation thus aggravating ED in diabetes. Given the very recent study reporting that overexpression of calpastatin improved EDHF-mediated ED in the aorta of mice with hyperglycemia \[[@R41]\]. Studies are warranted elucidating this therapeutically useful pathway because the role of activation of calpains on PGI2 and EDHF in diabetes remains unclear.
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![Schematic representation of the risk factors for calpains activation in the ECs. Ang II, angiotensin II; LDL, low density lipoprotein; VEGF, vascular endothelial growth factor.](nihms699131f1){#F1}

![Schematic representation of the role and signaling pathways of calpain activation in NO-mediated ED in diabetes. eNOS, endothelial nitric oxide synthase; ECs, endothelial cells; eNOS-pThr495/497, phosphorylation of eNOS at threonine 495/497; hsp90, ICAM-1, intercellular adhesion molecule 1; hsp90, heat shock proteins 90; NO, nitric oxide; VCAM-1, vascular cell adhesion molecule 1.](nihms699131f2){#F2}

###### 

Effects of calpains inhibition on ED in diabetic animal models.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Procedure for calpains inhibition                Animal                                                                                                     Vessels                               Effective dose                                                                                    Outcomes                                              Ref.
  ------------------------------------------------ ---------------------------------------------------------------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------- ------------
  MDL-28170                                        STZ-treated mouse                                                                                          Thoracic aorta                        2 mg/kg/day, i.p. 2 weeks                                                                         NO-mediated vascular relaxation to ACh↑               \[[@R15]\]

  MDL-28170, ALLM                                  STZ-treated mouse                                                                                          Thoracic aorta                        Aorta were preincubated with 20 μM of MDL-28170, ALLM or calpeptin for 1h, *ex vivo*              NO-mediated vascular relaxation to ACh↑               \[[@R15]\]

  siRNA against μ-calpain                          C57BL/6J mouse                                                                                             Thoracic aorta                        Vessels treated with D-glucose and μ-calpain siRNA for 72h, *in vitro*                            NO-mediated vascular relaxation to ACh↑               \[[@R15]\]

  ZLLal                                            C57BL6J mouse injected with D-glucose                                                                      Mesenteric artery                     18 μg/kg/day, i.p., one time                                                                      Leukocyte-endothelium interactions↓, NO production↑   \[[@R10]\]

  ZLLal                                            Zucker diabetic fatty rat                                                                                  Mesenteric artery                     27 μg/kg/day, i.p., 5 days                                                                        Leukocyte-endothelium interactions↓, NO production↓   \[[@R9]\]

  ZLLal and μ-calpain antisense oligonucleotides   Zucker diabetic fatty rat                                                                                  Mesenteric artery                     ZLLal: 27μg/kg/day, i.p., 4 days μ-calpain antisense oligonucleotides: 1mg/kg/day, i.p., 4 days   Microvascular albumin leakage↓                        \[[@R24]\]

  Over-expression of calpastatin                   Calpastatin transgenic/STZ-treated, calpastatin transgenic/db/db, and calpastatin transgenic/OVE26 mouse   Aorta                                                                                                                                   NO- and EDHF-mediated vascular relaxation to ACh↑     \[[@R41]\]

  ZLLal PD150606                                   STZ-treated rats                                                                                           Mesenteric post - capillary venules   ZLLal: 27 μg/kg/day, i.p., 4 days\                                                                Leukocyte-endothelium interaction↓                    \[[@R29]\]
                                                                                                                                                                                                    PD150606: 1mg/kg/day, i.p., 4 days                                                                                                                      

  MDL-28170                                        C57BL6J mouse                                                                                              Aorta                                 Aorta were treated with heavily oxidized' glycated LDL and MDL-28170 (20 μM) for 6h, *in vitro*   Vascular relaxation to ACh↑                           \[[@R40]\]

  A-705253                                         STZ-treated mouse                                                                                          Cavernosa                             30 mg/kg/day, 2 weeks                                                                             Cavernosa relaxation to ACh↑                          \[[@R13]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
